Arcus Biosciences (RCUS) Competitors $13.32 -0.08 (-0.57%) As of 01/23/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RCUS vs. GRFS, TGTX, AXSM, KRYS, VRNA, OGN, SRRK, ALVO, BHVN, and ADMAShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Grifols (GRFS), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Verona Pharma (VRNA), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Biohaven (BHVN), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Grifols TG Therapeutics Axsome Therapeutics Krystal Biotech Verona Pharma Organon & Co. Scholar Rock Alvotech Biohaven ADMA Biologics Arcus Biosciences (NYSE:RCUS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Which has more volatility and risk, RCUS or GRFS? Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Is RCUS or GRFS more profitable? Grifols has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Grifols' return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-102.66% -45.59% -22.38% Grifols N/A N/A N/A Which has better earnings & valuation, RCUS or GRFS? Grifols has higher revenue and earnings than Arcus Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$117M10.42-$307M-$3.15-4.23Grifols$7.13B0.72$64.20MN/AN/A Does the media refer more to RCUS or GRFS? In the previous week, Arcus Biosciences had 15 more articles in the media than Grifols. MarketBeat recorded 16 mentions for Arcus Biosciences and 1 mentions for Grifols. Grifols' average media sentiment score of 0.28 beat Arcus Biosciences' score of 0.28 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor RCUS or GRFS? Grifols received 155 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.54% of users gave Arcus Biosciences an outperform vote while only 56.02% of users gave Grifols an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes19465.54% Underperform Votes10234.46% GrifolsOutperform Votes34956.02% Underperform Votes27443.98% Do analysts rate RCUS or GRFS? Arcus Biosciences presently has a consensus target price of $34.00, indicating a potential upside of 155.18%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Grifols 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in RCUS or GRFS? 92.9% of Arcus Biosciences shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryArcus Biosciences beats Grifols on 9 of the 16 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.23B$6.59B$5.42B$20.04BDividend YieldN/A2.95%5.36%3.61%P/E RatioN/A6.4172.2938.26Price / Sales10.42335.141,254.5217.74Price / CashN/A66.9544.7020.41Price / Book2.165.185.055.78Net Income-$307M$154.67M$117.90M$1.01B7 Day Performance-4.76%3.43%2.62%1.38%1 Month Performance-16.25%1.53%3.64%5.03%1 Year Performance-12.63%7.13%27.49%19.26% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences1.9813 of 5 stars$13.32-0.6%$34.00+155.2%-13.7%$1.23B$117M0.00500Analyst RevisionHigh Trading VolumeGRFSGrifols1.7349 of 5 stars$7.27+0.4%N/A+1.6%$5.00B$7.01B0.0023,737Positive NewsGap DownTGTXTG Therapeutics4.504 of 5 stars$29.55+1.4%$40.67+37.6%+83.7%$4.60B$233.66M-295.47290Analyst RevisionPositive NewsAXSMAxsome Therapeutics4.6083 of 5 stars$91.93-1.9%$130.69+42.2%+16.1%$4.45B$270.60M-14.08380Analyst ForecastAnalyst RevisionKRYSKrystal Biotech4.9241 of 5 stars$148.39+2.5%$206.67+39.3%+18.9%$4.27B$50.70M83.84210VRNAVerona Pharma2.0366 of 5 stars$51.89-3.3%$50.57-2.5%+217.4%$4.22B$460,000.00-27.0330Analyst ForecastAnalyst RevisionOGNOrganon & Co.4.8698 of 5 stars$15.77-2.6%$21.33+35.3%+0.9%$4.06B$6.26B3.1310,000SRRKScholar Rock2.9095 of 5 stars$43.13-1.8%$40.43-6.3%+208.2%$4.04B$33.19M-18.35140Insider TradeALVOAlvotech2.0454 of 5 stars$13.27+0.3%$18.00+35.6%-7.9%$4.00B$93.38M-7.171,026BHVNBiohaven3.1051 of 5 stars$37.57+4.8%$63.00+67.7%-15.8%$3.80BN/A-4.02239Analyst RevisionADMAADMA Biologics4.1809 of 5 stars$16.02-3.7%$21.25+32.6%+214.6%$3.79B$382.81M57.21530Analyst Revision Related Companies and Tools Related Companies Grifols Competitors TG Therapeutics Competitors Axsome Therapeutics Competitors Krystal Biotech Competitors Verona Pharma Competitors Organon & Co. Competitors Scholar Rock Competitors Alvotech Competitors Biohaven Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RCUS) was last updated on 1/24/2025 by MarketBeat.com Staff From Our PartnersJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts